Summary: Elucidating the role of Bax inhibitor 1 (BI-1) and its mechanisms in the pathophysiology of hypoxic ischemic encephalopathy may help provide a basis for BI-1 as a potential therapeutic target in clinics. The gene discussed is TMBIM6; the disease is perinatal asphyxia.